Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Case reports of benign hepatoma in young women taking oral contraceptives (OCs) are known to exist. A benign hepatic adenoma was discovered in a young woman who had been taking an OC (Ortho-Novum 2) for 7 years. Although hepatic adenoma is a rare tumor, the increasing number of reports of its occurrence strongly suggest an association between OCs and benign hepatic adenoma. Diagnosis must be suspected in any young woman taking OCs and developing signs of acute cholecystitis with hepatomegaly or mass, or presenting with signs and symptoms of nontraumatic intraabdominal hemorrage. Rupture of the tumor is life-threatening. Treatment should be removal of the tumor whenever possible.
 ...
PMID:Benign liver cell adenoma associated with use of oral contraceptive agents. 17 59

The aim of our study was to confirm by Recombinant Immunoblot Assay (RIBA) and by neutralization assay the repeat positive reactions found by two commercially available EIAs (Ortho and Abbott) when testing samples from volunteer blood donors, patients with chronic liver disease and with hepatocellular carcinoma. Our data show a high confirmatory rate among patients with chronic viral NANBH and HCC, while among donors and patients with CLD other than NANBH the percentage of presumptive EIA positive reactions confirmed by RIBA and/or neutralization assay is much lower. In our experience, the neutralization assay appears to be somewhat more sensitive than RIBA, especially when samples show low EIA optical densities.
 ...
PMID:Confirmation of anti-HCV EIA reactivities by RIBA and neutralization assay among blood donors and patients with chronic liver disease and hepatocellular carcinoma. 133 25

Potential risk factors for the development of hepatocellular carcinoma were analysed in 40 Caucasian patients with this malignancy. A higher proportion (14 of 40; 35%) had evidence of hepatitis C virus (HCV) infection than had evidence of either hepatitis B virus (HBV) carriage (17.5%) or alcohol abuse (30%). In all 14 patients whose sera were reactive by HCV ELISA (Ortho second generation test), the presence of antibodies to HCV were confirmed by recombinant immunoblot assay (Ortho RIBA-2). Furthermore, two independent laboratories detected HCV-RNA in 10 of the 14 (71%) anti-HCV positive sera. Two additional sera were shown to contain HCV-RNA when reanalysed by a modified PCR using oligonucleotide primers designed to amplify a shorter fragment of the 5' noncoding region of the genome. Seven of the anti-HCV positive patients also had evidence of prior HBV infection and 2 admitted to alcohol abuse. HCV infection was the only identifiable risk factor in 6 patients. These data confirm the association between HCV infection and hepatocellular carcinoma and suggest that persistent viral replication accompanies tumour development in the majority of patients whose serum contains anti-HCV.
 ...
PMID:Detection of hepatitis C viraemia in Caucasian patients with hepatocellular carcinoma. 133 30

Blood specimens from 210 leprosy patients (average age 67.4 years old) and 84 staff members (average age 43.5 years old) in National Leprosarium Suruga were tested for anti-HCV antibody using Ortho's Ab ELISA system. Among the patients, 17 patients had chronic hepatic dysfunction as well as leprosy. Twenty of the 210 patients (9.5%) had anti-HCV antibody in their blood. Eleven of the 17 patients (65%) with chronic hepatic dysfunction were positive for anti-HCV antibody. Only one of the staff member was anti-HCV antibody positive. This high positive ratio of anti-HCV antibody in the leprosy patients is similar to the results of another research reported from National Leprosarium Oku Komyo-En. We, therefore, conclude that the prevalence of anti-HCV antibody in leprosy patients is higher than that of the general population and that anti-HCV antibody is related closely to chronic hepatic dysfunction. Some investigators have recently reported that there was an increased incidence of hepatocellular carcinoma in leprosy patients. And so, it is speculated that this is due to the high prevalence of the hepatitis C virus. However, the reason for this high prevalence of anti-HCV antibody in the sample is obscure.
 ...
PMID:[Survey of the antibody to HCV in National Leprosarium Suruga]. 133 73

In March 1989, ultrasonography revealed a hepatic mass in a 40 year old nulliparous woman who was then referred to the University of Southern California--Los Angeles (UCLA) Liver Unit. She exhibited no symptoms of a liver condition. From 19-28 years old, she took the combined oral contraceptive (OC) Ovulen 21 for irregular menses. After a brief period of taking Ortho Novum 1/80, she took Demulen 1/35-24 between ages 28-34. Her physician diagnoses endometriosis at 34. He stopped OC therapy and prescribed the progestin Norlutate. She had no history of hepatitis, toxin exposure, and previous liver disease. Further no one in her family had had liver disease or neoplasms. Computer tomography identified a 6.5 cm x 3.5 cm mass in the right lobe of the liver which matched a cold defect on a liver scan using technetium Tc 99m sulfur colloid. The mass selectively took up gallium. Arteriography revealed the mass to be a vascular tumor, but it did not exhibit a typical vascular pattern of an adenoma or the neovascularity of hepatocellular carcinoma. Physicians at UCLA used peritoneoscopy to take percutaneous needle biopsies of the right lobe which confirmed a hepatic adenoma. they then removed the right lobe of the liver. The remaining part of the liver was normal. Histologic examinations of the removed section showed features of a well differentiated hepatocellular carcinoma. Further tumor cells had invaded normal hepatic parenchyma. The physicians believed that hepatic adenoma was in the process of transforming into hepatocellular carcinoma in this patient. They thought that long term OC use, and possibly long term progestin use, may have contributed to the formation of the liver neoplasms. They emphasized the need for a pilot study to develop guidelines on surveillance ultrasonography of women taking OCs over a long period.
 ...
PMID:Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. 166 98

The aim of this study was to elucidate the positive rate of serum anti-HCV in alcoholic (with negative HBsAg and without blood transfusion history) and non-alcoholic (type-B and type-NANB) patients with chronic liver diseases. The clinico-pathological difference between anti-HCV positive and negative alcoholic patients was also investigated. Anti-HCV (Chiron C-100-3) was assayed with Ortho EIA kit in 196 patients. Liver function tests and the histological findings were evaluated in 111 cases of chronic hepatitis (CH) and 39 of liver cirrhosis (LC). Following results were obtained. [1] Positive rate of serum anti-HCV in alcoholic patients was 40% in CH, 36% in LC and 100% in hepatocellular carcinoma. In non-alcoholic type-NANB group, it was 75%, 68% and 69%, respectively. [2] Serum GGT/ALT ratio was higher in anti-HCV negative patients than positive patients both in CH and LC alcoholics. In non-alcoholic group, it was higher in type-NANB patients than type-B patients. [3] Among the histological findings in CH alcoholics, lymph follicles in the portal area were characteristic in anti-HCV positive patients, while these were not seen in negative patients. [4] In LC alcoholics, regenerative nodules were irregular in size in anti-HCV positive patients, while these were even and small in negative patients. [5] Serum HCV-RNA was detected in two out of 14 anti-HCV negative patients. [6] A female alcoholic patient who showed positive serum anti-HCV and negative HCV-RNA was presented. [7] For the evaluation of the influence of HCV in alcoholics, further studies have to be continued with more sensitive HCV markers.
 ...
PMID:[Positive rate of serum anti-HCV in various liver diseases and the clinico-pathological study of chronic liver disease in alcoholics]. 166 37

To determine the seroprevalence of hepatitis C virus in the Philippines and compare it with the seroprevalence of hepatitis B virus infection, HBV and HCV markers in 594 serum samples collected from 392 blood donors, 123 medical and paramedical personnel, and 80 patients (45 liver diseases: 25 acute hepatitis, 9 liver cirrhosis, and 11 hepatocellular carcinoma; 28 hepatitis B carriers, and 7 chronic renal failure patients undergoing dialysis) in Davao, Mindanao Island, Philippines, were examined. HBsAg was determined by RPHA, anti-HBc by HI, anti-HBs by PHA, and HBsAg subtypes, HBeAg, and anti-HBe by EIA. HCV markers determined were anti-HCV (anti-C100-3) by ELISA (Ortho Diagnostic Systems), and anti-HCV core (anti-CP9 and/or anti-CP10) also by ELISA. Results showed that 9 (2.2%) blood donors were anti HCV positive; 69 (15.4%) were anti-HCV core positive Nine (2.2%) were HBsAg carriers; 240 (61.3%) were anti-HBs and/or anti-HBc positive (HBsAg carriers excluded from this group). Two of 123 medical and paramedical staff (1.6%) were anti-HCV positive; 11 (8.1%) were anti-HCV core positive; Eight (6.5%) were HBsAg carriers and 81 (65.8%) anti-HBs and/or anti-HBc positive. Five of 11 (45.4%) hepatocellular carcinoma patients were HBsAg carriers; 2 were anti-HCV core positive. Two of 9 liver cirrhosis patients were anti-HCV positive (1 to anti-HCV and the other to anti-HCV core).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Seroepidemiology of hepatitis C virus infection in the Philippines: a preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines. 190 61

The seroepidemiology of HBV and HCV infections in the patients with acute and chronic liver diseases in Jakarta was investigated. The sera from 141 cases with acute hepatitis, 176 liver cirrhosis and 70 hepatocellular carcinoma (HCC) were examined. Anti-HA IgM, HBsAg, anti-HBc IgM and anti HCV (Ortho) were detected by Elisa method. In acute hepatitis, 83 cases (58.9%) out of 141 cases were hepatitis A and 9 cases (6.4%) hepatitis B. The others were diagnosed non-A, non-B (NANB) hepatitis and anti-HCV in 4 cases (11.8%) out of 34 cases with NANB hepatitis was positive. The low prevalence of anti-HCV in acute NANB hepatitis seems to be due to inadequate date of serum sampling. HBsAg and anti-HCV in liver cirrhosis were positive 36.5% and 73.9% respectively, including 22.7% of double infection. HBsAg and anti-HCV in HCC were 58.6% and 34.2%, including 17.1% of double infection. In 16.7% fo chronic liver disease (liver cirrhosis and HCC), neither HBsAg nor anti-HCV were detected.
 ...
PMID:The prevalence of antibody to hepatitis C virus (anti-HCV) in patients with acute and chronic liver diseases in Jakarta, Indonesia. 190 63

A survey was performed to investigate HBV and HCV infection in Ujung Pandang. The total number of subjects was 406; 196 blood donors, 78 cases of acute hepatitis, 43 of chronic hepatitis, 58 of liver cirrhosis and 31 of hepatocellular carcinoma cases. HBsAg, anti-HBs and anti-HBc as HBV markers and anti-HCV (ELISA, Ortho) as an HCV marker were tested. Positive rates of HBsAg and anti HCV among blood donors were 7.1% and 3.1% respectively, and there was no significant difference among age groups. Donors negative for all viral markers accounted for 21.4%. Of acute hepatitis cases, 18 (23.1%) cases were hepatitis A and 8 (10.3%) cases were hepatitis B, one case of which was considered to be double infection. Acute exacerbation cases of HBV carriers were 16 (20.5%), of which 6 cases were positive for HCV antibody. Those diagnosed non-A, non-B hepatitis were 37 (47.4%), of which 3 cases where positive for HCV antibody. Blood samples from all of acute hepatitis cases were obtained within 1 week after onset of the disease, thus, it was not possible to accurately assess prevalence of hepatitis C. Positive rates on HBsAg among chronic hepatitis, liver cirrhosis and hepatocellular carcinoma were 25.4%, 32.8% and 35.5% respectively, while those for HCV antibody were 16.3%, 43.1% and 35.5% respectively. Positive rates of HBsAg and HCV antibody for overall chronic liver diseases were 31.1% and 32.6%, and 14 (10.6%) were positive for both markers.
 ...
PMID:Hepatitis B and C virus infection in Ujung Pandang, Indonesia. 190 64

Antibodies against hepatitis C (HCV) in 512 patients were measured by an enzyme immunoassay (Ortho-HCV ELISA). The frequency of anti-HCV was 80%, 86%, 85% in nonB (NB) chronic hepatitis (CH), cirrhosis (LC), hepatocellular carcinoma (HCC), respectively; 70%, 90% in alcoholic (AL) LC, HCC; 15%, 33%, 58% in hepatitis B (HB) CH, LC, HCC, respectively. Anti-HCV positive cirrhotics had a shorter survival time and earlier development of HCC than anti-HCV negative cirrhotics. The findings suggest that HCV is a major cause of NB chronic liver diseases and may play a pathogenetic role in AL and HB liver diseases.
 ...
PMID:Hepatitis C virus infection in patients with chronic liver diseases. 190 68


1 2 3 Next >>